1) at Uskmouth: results from fuel testing in Japan. If successful, the immediate TAM for SAE would essentially be limitless. 2,500 coal-fired power plants worldwide. A 200 MW... 1/8
...plant, once converted, would generate £40m+ (arguably closer to £60m) EBITDA pa for a further 20+ years. It would also burn more efficiently and more cleanly than it previously did, when coal-powered. Decom costs can be well over £10m - as such, there's a huge market for...2/8
…#SAE to pick up end-of-life plants for next to nothing.
Moreover, as the operation is so reliable, 100% debt financing (conventional or receivables) for conversion capex could should be achievable.
Uskmouth will be the blue print for global rollout of the conversion. 3/8
2) at MeyGen: the UK gov itself has proposed a restructuring of the pots for the next round of CfDs (2021).
[In short, CfDs are governmental support (via buying electricity at higher prices) to encourage the development of renewable energy technologies.]
The gov is... 4/8
...proposing to take offshore (fixed) wind out of the pot that tidal power is in, and put it in a pot of its own. The rationale is to enable offshore (floating) wind and tidal to have a greater chance of winning the CfDs (i.e. revenue support).
The gov is now reviewing... 5/8
...the public's response to the proposal - but I would suggest that the gov proposed these measures in the first place precisely because of industry participants pushing for it.
Needless to say, a change in the CfD structure would open up massive support for #SAE's MeyGen. 6/8
The project lease has a further 392 MW of capacity to develop: with gov financial support, industrials and infrastructure funds would be much, much more interested in financing the development of MeyGen.
That whole process would itself lower the LCOE of tidal, validating... 7/8
..its commercial viability to the world.
To summarise, in the coming months #SAE could receive two items of news that would enable it to become a leading global player in 2 potentially vast markets, that are both highly topical.
2nd largest position, and I continue to add. 8/8
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6